Get the Stockscreener App
16.61
0.27%
0.045
Contineum Therapeutics Inc stock is traded at $16.61, with a volume of 16,007.
It is up +0.27% in the last 24 hours and down -2.32% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$16.56
Open:
$16.7
24h Volume:
16,007
Relative Volume:
0.24
Market Cap:
$425.98M
Revenue:
-
Net Income/Loss:
$-31.45M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-33.15M
1W Performance:
-3.18%
1M Performance:
-2.32%
6M Performance:
+17.85%
1Y Performance:
+0.00%
1-Day Range:
$16.50
$16.88
1-Week Range:
$16.41
$17.40
52-Week Range:
$13.27
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
Contineum Therapeutics Inc Stock (CTNM) Latest News
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Baird R W - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W - MarketBeat
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials - Investing.com Canada
Contineum stock draws bullish view at Baird (CTNM:NASDAQ) - Seeking Alpha
Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird - MarketBeat
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials By Investing.com - Investing.com South Africa
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Simply Wall St
Objective long/short (CTNM) Report - Stock Traders Daily
The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Yahoo Finance
Financial Metrics Exploration: Understanding Contineum Therapeutics Inc. (CTNM) Through Ratios - The Dwinnex
Squarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
SEC Form 4 filed by EVP, Chief Human Resourses Ofc Devers Shannon L. - Quantisnow
New insider Devers Shannon L. claimed ownership of 7,909 shares (SEC Form 3) - Quantisnow
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - Yahoo Finance
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World
Perceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com
Bank of New York Mellon Corp Invests $356,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat
Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat
CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World
Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World
BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World
NET Power Inc. (NYSE:NPWR) Major Shareholder Sells $12,348.00 in Stock - Defense World
Direxion Daily MSFT Bull 2X Shares Announces Quarterly Dividend of $0.33 (NASDAQ:MSFU) - Defense World
Hilton Worldwide Holdings Inc. (NYSE:HLT) Shares Acquired by Xponance Inc. - Defense World
Blue Star Gold (CVE:BAU) Shares Down 9.1% - Defense World
Bank of Nova Scotia (TSE:BNS) Lifted to “Strong-Buy” at Cibc World Mkts - Defense World
Zacks Research Comments on Vail Resorts, Inc.’s FY2024 Earnings (NYSE:MTN) - Defense World
Mill Creek Capital Advisors LLC Makes New Investment in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Evergreen Capital Management LLC Acquires 519 Shares of BlackRock, Inc. (NYSE:BLK) - Defense World
Origin Enterprises (LON:OGN) Sets New 12-Month High After Dividend Announcement - Defense World
Q3 2024 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Wedbush - Defense World
Kenvue (NYSE:KVUE) Downgraded by Royal Bank of Canada - Defense World
Ionis Plans $500M Public Offering - San Diego Business Journal
Contineum Therapeutics (NASDAQ:CTNM) Sees Strong Trading Volume - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Sees Large Volume Increase - MarketBeat
Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier - Audacy
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Amplify Alternative Harvest ETF (NYSEARCA:MJ) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Intercede locks in further contract orders and renewals - ShareCast
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):